In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Charles River Laboratories International Inc.

www.criver.com

Latest From Charles River Laboratories International Inc.

Time For AI To Deliver In Drug Discovery, Says Atomwise CEO

Having signed a multi-year, multi-target agreement with Lilly worth potentially $550m, Atomwise CEO Abe Heifets tells Scrip the burden of proof is on AI practitioners to start producing relevant and actionable data.

Artificial Intelligence Companies

Merck Makes Its Debut In Pain With Pioneering New Analgesic Class

Merck & Co is moving into analgesia with a deal signed with Kings College London for an early program that has the potential to create a novel class of pain medications with reduced side effects.

Innovation Deals

Doubling Up On Vaccines: A Combined Zika And Dengue Vaccine May Be Possible

The global research effort to halt the spread of Zika virus now includes candidate vaccines from the US NIH, Takeda and Moderna Therapeutics.

 

Vaccines Infectious Diseases

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

BioPharmaceutical Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register